Patents by Inventor Lawrence R. McGee

Lawrence R. McGee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100113522
    Abstract: Modulators of PPAR? activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Application
    Filed: October 13, 2009
    Publication date: May 6, 2010
    Applicant: Amgen Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Patent number: 7626033
    Abstract: Modulators of PPAR? activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: December 1, 2009
    Assignee: AMGEN INC.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Patent number: 7601841
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR?. In particular, the compounds of the invention modulate the function of PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: October 13, 2009
    Assignees: Amgen Inc., Japan Tobacco, Inc.
    Inventors: Lawrence R. McGee, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
  • Publication number: 20090221584
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: November 12, 2008
    Publication date: September 3, 2009
    Inventors: Philippe Bergeron, Christopher N. Farthing, Stuart D. Jones, John W. Liebeschuetz, Sarah E. Lively, Lawrence R. McGee, Sharon McKendry, David Sheppard, Stephen C. Young
  • Publication number: 20090221635
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR?. In particular, the compounds of the invention modulate the function of PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: February 17, 2009
    Publication date: September 3, 2009
    Applicants: Amgen Inc., Japan Tobacco. Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
  • Publication number: 20090149648
    Abstract: Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.
    Type: Application
    Filed: September 16, 2008
    Publication date: June 11, 2009
    Applicant: Gilead Sciences, Inc.
    Inventors: Norbert W. Bischofberger, Robert J. Jones, Murty N. Armilli, Kuei-Ying Lin, Michael S. Louie, Lawrence R. McGee, Ernest J. Prisbe, William A. Lee, Kenneth C. Cundy
  • Patent number: 7544702
    Abstract: Bisaryl-sulfonamide compounds having the formula wherein Ar, R1, R2, L, B, W, X, Y, and Z, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: June 9, 2009
    Assignee: Amgen Inc.
    Inventors: Philippe Bergeron, Christopher N. Farthing, Stuart D. Jones, John W. Liebeschuetz, Sarah E. Lively, Lawrence R. McGee, Sharon McKendry, David Sheppard, Stephen C. Young
  • Publication number: 20090137581
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: March 24, 2008
    Publication date: May 28, 2009
    Inventors: Yi Chen, Timothy D. Cushing, Jason A. Duquette, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Brian Lucas, Lawrence R. McGee, Andreas Reichelt, Robert M. Rzasa, Jennifer Seganish, Youngsook Shin, Dawei Zhang
  • Patent number: 7439350
    Abstract: Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.
    Type: Grant
    Filed: June 29, 2004
    Date of Patent: October 21, 2008
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert W. Bischofberger, Robert J. Jones, Murty N. Arimilli, Kuei-Ying Lin, Michael S. Louie, Lawrence R. McGee, Ernest J. Prisbe, William A. Lee, Kenneth C. Cundy
  • Patent number: 7439242
    Abstract: Modulators of PPAR? activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: October 21, 2008
    Assignee: Amgen Inc.
    Inventors: Jonathan B. Houze, Lawrence R. McGee, Steven Marc Rubenstein
  • Patent number: 7223761
    Abstract: Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: May 29, 2007
    Assignee: Amgen Inc.
    Inventors: Henry T. Kruk, Lawrence R. McGee, Bing Yang
  • Patent number: 7041691
    Abstract: Modulators of PPAR? activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: May 9, 2006
    Assignee: Amgen Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Publication number: 20040248882
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Application
    Filed: March 25, 2004
    Publication date: December 9, 2004
    Applicant: Tularik Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Publication number: 20040242465
    Abstract: Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.
    Type: Application
    Filed: June 29, 2004
    Publication date: December 2, 2004
    Inventors: Norbert W. Bischofberger, Robert J. Jones, Murty N. Arimilli, Kuei-Ying Lin, Michael S. Louie, Lawrence R. McGee, Ernest J. Prisbe, William A. Lee, Kenneth C. Cundy
  • Publication number: 20040176409
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&ggr;. In particular, the compounds of the invention modulate the function of PPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: November 20, 2003
    Publication date: September 9, 2004
    Applicants: Tularik Inc, Japan Tobacco, Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
  • Patent number: 6770648
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: August 3, 2004
    Assignee: Tularik Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Patent number: 6620827
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: September 16, 2003
    Assignee: Tularik Inc.
    Inventors: Fabienne De la Brouse-Elwood, Jin-Long Chen, Timothy D. Cushing, John A. Flygare, Jonathan B. Houze, Juan C. Jaen, Lawrence R. McGee, Shi-Chang Miao, Steven Marc Rubenstein, Patrick C. Kearney
  • Publication number: 20030171399
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&ggr;. In particular, the compounds of the invention modulate the function of PPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: October 21, 2002
    Publication date: September 11, 2003
    Applicant: Tularik Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
  • Publication number: 20030139390
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Application
    Filed: July 30, 2002
    Publication date: July 24, 2003
    Applicant: Tularik Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein
  • Patent number: 6583157
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PAPAR&ggr;. In particular, the compounds of the invention modulate the function of PAPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: June 24, 2003
    Assignees: Tularik Inc., Japan Tobacco, Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai